Amgen (NASDAQ:AMGN) says data from Phase 3 tests for its immune thrombocytopenia drug Nplate showed postitive results, and was presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology over the weekend in San Diego.
Amgen (NASDAQ:AMGN) says data from Phase 3 tests for its immune thrombocytopenia drug Nplate showed postitive results, and was presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology over the weekend in San Diego.